Drug Trial Radar · NCT05718895
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Mar 27, 2023
Primary completion
Dec 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Antengene Biologics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
ATG-022Drug
Dose Escalation Phase: A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of "3+3" design.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: Up to 21 Days
- MTDTime frame: Up to 21 Days
- RP2DTime frame: Up to 21 Days
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Cancer Research SA Pty Ltd
Adelaide, Australia · Completed
Cabrini Health Limited
Malvern, Australia · Recruiting
Integrated Clinical Oncology Network Pty Ltd (Icon)
South Brisbane, Australia · Recruiting
Beijing GoBroad Hospital
Beijing, China · Recruiting
West China Hospital, Sichuan University
Chengdu, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Anhui Provincial Hospital
Hefei, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, China · Recruiting
Jinan Central Hospital
Jinan, China · Recruiting
Gansu provincial cancer hospital [recruiting]
Lanzhou, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Tongren Hospital Shanghai
Shanghai, China · Recruiting
Liaoning Cancer Hospital
Shenyang, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiangzhuang, China · Recruiting
Shanxi provincial cancer hospital
Taiyuan, China · Recruiting
Tianjin Medical Universuty Cancer Institute & Hospital
Tianjin, China · Recruiting
Hubei Cancer Hospital
Wuhan, China · Recruiting
The First affiliated hospital of Xi'An Jiao Tong Ubiversity
Xi'an, China · Recruiting
Xuzhou Central Hospital
Xuzhou, China · Recruiting
General Hospital of Ningxia Medical University
Yinchuan, China · Recruiting
The First Affiliated Hospital of Zhenghzou University
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.